Ligand Pharma (LGND) introduces 2023 financial guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Ligand Provides Highlights from its Investor and Analyst Day Event
December 13, 2022 8:30 AM ESTExecutive Management Reviewed Business Model and Growth Drivers Following the Successful Spin-Off of OmniAb, Introduced 2023 Financial Guidance
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at todays Investor and Analyst Day event its executive management provided an overview of Ligands corporate structure and business following the successful spin-off of its OmniAb antibody discovery business, reviewed Ligands recent progress and near-term partner milestones and provided an outlook for financial growth. Management also introduced 2023 financial guidance and discussed its capital deployment strategy. A webcast... More
